NeuroPace (NASDAQ:NPCE – Get Free Report) and Solana (NASDAQ:HSDT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
Risk and Volatility
NeuroPace has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Solana has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Insider & Institutional Ownership
78.8% of NeuroPace shares are held by institutional investors. Comparatively, 18.6% of Solana shares are held by institutional investors. 20.5% of NeuroPace shares are held by company insiders. Comparatively, 14.4% of Solana shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| NeuroPace | -21.67% | -108.20% | -18.50% |
| Solana | -1,427.15% | -67.57% | -24.09% |
Analyst Ratings
This is a summary of current ratings and recommmendations for NeuroPace and Solana, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroPace | 1 | 1 | 4 | 2 | 2.88 |
| Solana | 1 | 1 | 1 | 1 | 2.50 |
NeuroPace presently has a consensus price target of $18.83, indicating a potential upside of 15.40%. Solana has a consensus price target of $3.50, indicating a potential upside of 150.00%. Given Solana’s higher possible upside, analysts plainly believe Solana is more favorable than NeuroPace.
Earnings and Valuation
This table compares NeuroPace and Solana”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroPace | $99.99 million | 5.56 | -$21.47 million | ($0.65) | -25.11 |
| Solana | $6.02 million | 13.58 | -$40.89 million | ($109.67) | -0.01 |
NeuroPace has higher revenue and earnings than Solana. NeuroPace is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroPace beats Solana on 11 of the 15 factors compared between the two stocks.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
About Solana
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
